Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL607047 | 1.00 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL98410 | 0.95 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Hydrochloric Acid SCHEMBL10584588 | 0.94 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Water SCHEMBL27625510 | 0.94 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Pyrophosphoric Acid SCHEMBL2800166 | 0.93 | P2RY6 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Triphosphate SCHEMBL28074755 | 0.91 | P2RY6 (0.49) | P2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL425422 | 0.85 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2176031 | 0.85 | P2RY6 (0.47) | P2RY14P2RY2P2RY6P2RY4 | |
| Phosphoric Acid SCHEMBL21465157 | 0.85 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL18486662 | 0.84 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357617-B2 | Discovery of novel anti-infectives for gram negative pathogens | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| CN-114206896-B | Cyclic deoxyribonucleotide compounds | 纽科利制药公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3538151-B1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INST BIOMEDICAL RES (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117563014-A | Antibody-drug gene conjugate and application thereof | 上海交通大学 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023018718-A1 | MICROBIAL APPROACH FOR THE PRODUCTION OF LONG CHAIN COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230051644-A1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-16 | — | — | US | disclosed |
| US-11453858-B2 | Human plasma-like medium | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220031672-A1 | DISCOVERY OF NOVEL ANTI-INFECTIVES FOR GRAM NEGATIVE PATHOGENS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2020072976-A1 | DISCOVERY OF NOVEL ANTI-INFECTIVES FOR GRAM NEGATIVE PATHOGENS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20190352598-A1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2019-11-21 | — | — | US | disclosed |
| EP-1100964-A1 | GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | Variagenics, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000004194-A1 | GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | VARIAGENICS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5859295-A | Canavanine analogs and their use as chemotherapeutic agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5552440-A | Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031672-A1 | DISCOVERY OF NOVEL ANTI-INFECTIVES FOR GRAM NEGATIVE PATHOGENS | BET1, BOLA2; BOLA2B, BRD2 | SLC28A1 3945/4885SLC28A2 3545/4885SLC29A1 2928/4885 |
| US-12357617-B2 | Discovery of novel anti-infectives for gram negative pathogens | BET1, BOLA2; BOLA2B, BRD2 | SLC28A1 3945/4885SLC28A2 3545/4885SLC29A1 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.